Moderna Expects To Add $10B-$15B In Annual Sales Five Years After Launching New Products In Oncology, Rare, And Latent Diseases By 2028. This Is In Addition To The Previously Announced $8B-$15B Of Expected Sales From The Respiratory Franchise In 2027
Portfolio Pulse from Benzinga Newsdesk
Moderna plans to add $10B-$15B in annual sales by 2028 from new products in oncology, rare, and latent diseases. This is in addition to the previously announced $8B-$15B of expected sales from the respiratory franchise in 2027. The company will invest approximately $25 billion in research and development from 2024 through 2028 to support this growth.
September 13, 2023 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's planned investment in R&D and new product launches in oncology, rare, and latent diseases are expected to significantly boost its annual sales by 2028.
Moderna's significant investment in R&D and the launch of new products in various disease areas are expected to drive its revenues significantly higher by 2028. This is likely to have a positive impact on its stock price in the short term as it indicates strong future growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100